Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Breast Neoplasms × Immunotherapy × Clear all

Phase

Status

Active not recruiting 3 Terminated 1 Recruiting 1 Not yet recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Rectal Neoplasms 3 Lung Neoplasms 2 Unresectable Hepatocellular Carcinoma 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor Cancer 1 Sarcoma 1 Radiation Injuries 1 Pathologic Complete Response 1 Pancreatic Cancer Liver Metastases 1 Neoplasms 1 Neoadjuvant Immunotherapy 1 Muscle-invasive Bladder Cancer 1 Locally Advanced Pancreatic Cancer 1 Hyperthermia 1 HER2-Negative Locally Advanced Breast Cancer 1 Gastrointestinal Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma 1 Breast Neoplasms 1 Advanced Rectal Cancer 1

Interventions

Capecitabine 16 Trastuzumab 13 pertuzumab 12 Letrozole 11 Docetaxel 11 Cyclophosphamide 11 pyrotinib 9 Paclitaxel 9 Carboplatin 9 sacituzumab govitecan 7 palbociclib 7 abemaciclib 7 Fulvestrant 7 trastuzumab deruxtecan 6 Tamoxifen 6 Radiotherapy 6 Epirubicin 6 Drug Therapy 6 Anastrozole 6 eribulin 5 dalpiciclib 5 Vinorelbine 5 Standard of Care 5 Neoadjuvant Therapy 5 exemestane 4 Sentinel Lymph Node Biopsy 4 Gemcitabine 4 Doxorubicin 4 ribociclib 3 pembrolizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07254858 2025-11-28

CISN-L

First Affiliated Hospital of Wenzhou Medical University

Phase 2 Not yet recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡